<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2017-11-17 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled "Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry." The draft guidance, when finalized, will provide stakeholders engaged in the development of regenerative medicine therapies with FDA's current thinking on the expedited development and review of these products. The draft guidance describes the expedited programs available to spons...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2017-24837</p>
    <p><strong>Publication Date:</strong> 2017-11-17</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2017/11/17/2017-24837/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for">https://www.federalregister.gov/documents/2017/11/17/2017-24837/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2017-24837</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
